Standard of care for patients diagnosed with advanced CRC is surgery followed by adjuvant chemotherapy, most commonly the FOLFOX regimen. Physical incompatibilities between FOLFOX’s three component APIs (5-FU, LV and oxaliplatin) prevent “single solution” intravenous administration – instead, each API is separately administered through a central line. This serial administration has been shown to reduce efficacy.
Numerous adverse events arise as a consequence of FOLFOX administration and very high pH, including phlebitis, catheter blockage, sepsis and cold hypersensitivity. Collectively, these adverse events lead to poor patient outcomes via unacceptable levels of treatment interruption and discontinuation. Deflexifol promises to reduce the prevalence of these adverse events.